Definium Therapeutics, Inc. (DFTX) SEC Filings & Earnings Calls

Regulatory and commercial risks for psychedelic drug development; Schedule I substance status.

“Cautionary note regarding regulatory matters: lysergide and MDMA are Schedule I substances.”

Regulatory risk: DT120 ODT contains lysergide, a Schedule I substance, requiring DEA rescheduling for commercialization.

“DT120 ODT is a proprietary, pharmaceutically optimized form of lysergide D-tartrate... Lysergide and MDMA are Schedule I substances under the Controlled Substances Act.”

Net loss significantly increased due to non-cash warrant liability fair value change ($86.2M).

“Net loss for the three months ended June 30, 2026 was significantly impacted by an $86.2 million non-cash increase in the fair value of warrant liabilities associated with the appreciation in the Company's share price during the period.” · word for word

Clinical trial risks for remaining pipeline studies (GAD, PTSD) and regulatory approval uncertainty.

“Topline results from Phase 3 GAD studies of DT120 ODT in generalized anxiety disorder (GAD) on track: Voyage results anticipated week of August 10; Panorama results anticipated September 2026.” · word for word

Clinical trial failure risk

“We have not earned any revenue or reached commercialization of any of our product candidates.” · word for word

Dilution risk

“To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders could be diluted.” · word for word

Regulatory approval risk

“We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if it will occur at all.” · word for word

Dilution from offering; use of proceeds for R&D and commercialization carries execution risk.

“Offering of 23.7M shares at $34.00; proceeds used for R&D, potential commercialization, and working capital.”

Clinical trial success reduces pipeline risk; regulatory approval and commercialization still uncertain.

“Positive topline data from Phase 3 Emerge study; further trials and FDA approval required.”

Potential dilution of ~4.6% based on current outstanding shares.

“5,000,000 additional shares vs 109,066,783 outstanding”

Clinical trial failure risk; no revenue or approval timeline.

“Phase 3 trial initiation; no prior revenue from DT120.”

Clinical trial failure risk: three Phase 3 readouts in 2H 2026; any negative result could impair pipeline value.

“Three pivotal data readouts for DT120 ODT anticipated within the next five months.” · word for word

Cash burn acceleration: R&D and G&A expenses growing faster than cash base; runway may shorten if trials expand.

“R&D +77% YoY, G&A +101% YoY; cash $373.4M vs $411.6M at year-end 2025.”

Clinical trial failure risk

“We have not earned any revenue or reached commercialization of any of our product candidates.” · word for word

Financing risk

“We will continue to require substantial additional capital to develop our product candidates and to fund operations for the foreseeable future.” · word for word

Regulatory risk

“We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates” · word for word

Dilution risk

“To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders could be diluted” · word for word

Clinical trial failure risk

“We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders.” · word for word

Dilution risk from equity plan increase

“To consider and, if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the “2025 Equity Incentive Plan”) to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan (“ Proposal No. 3 ”) by 5,000,000 common shares” · word for word

Cash burn / financing dependency

“Enhanced our financial resources with $259 million in gross proceeds from equity financing in the fourth quarter of 2025.” · word for word

Clinical trial failure risk; all value depends on Phase 3 readouts

“Pre-revenue; no approved products; pipeline entirely dependent on DT120 ODT Phase 3 results”

Clinical Trial Failure Risk

“We cannot give any assurance that any of our product candidates will successfully complete clinical trials or receive regulatory approval” · word for word

Capital Requirement Risk

“We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs” · word for word

Regulatory and Controlled Substance Risk

“Our product candidates are controlled substances, the use of which may generate public controversy.” · word for word

Preliminary cash estimate subject to change; clinical trial risks.

“preliminary and subject to completion” · word for word

Pre-revenue biotech with significant cash burn; R&D expenses increasing; no approved products.

“Research and Development (R&D). R&D expenses were $31.0 million for the quarter ended September 30, 2025, compared to $17.2 million for the quarter ended September 30, 2024, an increase of $13.8 million. Cash, Cash Equivalents and Investments. As of September 30, 2025, MindMed had cash, cash equivalents and investments totaling $209.1 million compared to $27” · word for word

Clinical trial risk; Phase 3 data readouts in 2026; potential for failure.

“Enrollment is on track in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD. Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026.” · word for word

No revenue and history of losses

“To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates” · word for word

Dependence on future financing

“We will continue to require substantial additional capital to develop our product candidates and to fund operations for the foreseeable future.” · word for word

Clinical trial risk

“We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business.” · word for word

Regulatory approval uncertainty

“We do not know when, or if it will occur at all.” · word for word

Dilution risk from equity offerings

“To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders could be diluted” · word for word

Dilution from issuance of 21.1M new shares.

“18,375,000 common shares ... option to purchase up to an additional 2,756,250 Common Shares ... exercised by the Underwriters in full”

Preliminary financial data subject to adjustment; not audited or reviewed by independent accountants.

“This estimate of cash, cash equivalents and investments is preliminary and subject to completion. KPMG LLP has not audited, reviewed, compiled or completed its procedures.” · word for word

Clinical-stage biotech with no approved products; significant reliance on clinical trial success and regulatory approval.

“Forward-looking statements highlight risks: clinical trial risks, regulatory approval processes, novelty of psychedelic inspired medicines industry.”